Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Eli Lilly (NY: LLY)
119.77 USD  +1.10 (+0.93%)
Official Closing Price  /  Updated: 4:49 PM EST, Dec 5, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,944,318
Open 118.40
Bid (Size) 119.00 (2)
Ask (Size) 120.00 (9)
Prev. Close 118.67
Today's Range 117.54 - 119.92
52wk Range 101.36 - 132.13
Shares Outstanding 1,085,430,420
Dividend Yield 1.88%
Performance
YTD
+4.26%
+4.26%
1 Month
+5.89%
+5.89%
3 Month
+5.76%
+5.76%
6 Month
+2.35%
+2.35%
1 Year
+2.79%
+2.79%
Top News
More News
Lilly Announces New Leadership and Strategy in Oncology Research and Development
New organization to combine speed and agility of Loxo with scale and capabilities of Lilly Read More
from PR Newswire
Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer... Read More
from PR Newswire
More News
Read More
Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco
from PR Newswire
Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)
from PR Newswire
Advanced Medical Technologies Help Stem the Evergrowing Spread of Ailments
from PR Newswire
Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug
category General , Health/Care , Analyst , and 10 more.
from MarketWatch
REFILE-Eli Lilly to put Loxo executives in charge of new cancer research unit
category companyNews
from Reuters: Company News
Eli Lilly & Co (LLY)
from Comtex SmarTrend® News Briefs
EMBARGOED-Eli Lilly to put Loxo executives in charge of new cancer research unit
category companyNews
from Reuters: Company News
Eli Lilly Takes Over #73 Spot From Philip Morris International
category ETFs
from ETF Channel
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade
category Analyst Ratings , Benzinga , ESALY , and 11 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.